#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Kris Kanellopoulos Email
Executive Director . CTI BioPharma
Seattle, WA
Locationk*************@ctibiopharma.com
Primary EmailHow to contact Kris Kanellopoulos
Join and see Kris's contact info for free!Current Roles
Employees:
211Revenue:
$32.7MAbout
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.CTI BioPharma Address
3101 Western Ave., #600Seattle, WA
United States